Last reviewed · How we verify
NCT04003181
The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon
NA trial testing Antibiotics in Colon Adenocarcinoma in 64 participants. Completed in 26 May 2021.
26 May 2021
Quick facts
| Lead sponsor | University of Aarhus |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | factorial |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 64 |
| Start date | 28 September 2017 |
| Primary completion | 26 May 2021 |
| Estimated completion | 26 May 2021 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Antibiotics — full drug profile →
- Bile Acid Binder — full drug profile →
Conditions studied
- Colon Adenocarcinoma — all drugs for Colon Adenocarcinoma →
- Diarrhea — all drugs for Diarrhea →
Sponsor
University of Aarhus
Who can join
18 and older, any sex, with Colon Adenocarcinoma or Diarrhea. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Many patients suffer from chronic diarrhoea after surgical treatment for cancer in the right side of the colon. The investigators' main hypothesis is that colon cancer patients with chronic diarrhoea have a higher risk of bile acid malabsorption compared with colon cancer patients without diarrhoea. The investigators also expect that a part of the cases of bile acid malabsorption is caused by underlying bacterial overgrowth in the small bowel. The investigators assume that patients with severe bile acid malabsorption have a lower value of FGF19 in the blood compared to patients with moderate or none bile acid malabsorption. Furthermore, it is assumed that patients with chronic diarrhoea and documented bile acid malabsorption after surgical treatment for right-sided colon cancer will get improved bowel function when treated with a bile acid binder, or antibiotics in case of bacterial overgrowth.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Bidirectional interaction between intestinal microbiome and cancer: opportunities for therapeutic interventions.
Dutta D, Lim SH. · · 2020 · cited 42× · PMID 32817793 · DOI 10.1186/s40364-020-00211-6 -
The Lung Microbiota and Lung Cancer: A Growing Relationship.
Bou Zerdan M, Kassab J, Meouchy P, Haroun E, et al · · 2022 · cited 30× · PMID 36230736 · DOI 10.3390/cancers14194813
Verify or expand the search:
- PubMed search for NCT04003181
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Antibiotics
Trials testing the same drug.
- NCT07542314 — Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a · Phase 4 · not yet recruiting
- NCT06696859 — Patterns of Antibiotics Resistance · not yet recruiting
- NCT06377397 — Selective Antibiotics When Symptoms Develop Versus Universal Antibiotics for Preterm Neonates · Phase 3 · not yet recruiting
- NCT06483971 — Comparison of Oral Isotretinoin vs Ancomparison of Oral Isotretinoin vs Antibiotics on Corneal Thickness With AV · NA · active not recruiting
- NCT05813184 — Prenatal Antibiotics and Breast Milk / Neonatal IgA · recruiting
Other recruiting trials for Colon Adenocarcinoma
Currently open trials in the same condition.
- NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
- NCT06997497 — A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-108 · Phase 3 · recruiting
- NCT06652672 — Sentinel Node and Organ-sparing Surgery in Stage I Colon Carcinoma · NA · recruiting
- NCT06709885 — HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer · Phase 2 · recruiting
- NCT06640166 — Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Co · Phase 2 · recruiting
Other University of Aarhus trials
Trials by the same sponsor.
- NCT07209540 — European LUpuS Inception-Cohort Developing initiATivE · not yet recruiting
- NCT07317401 — Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Post-Viral Myalgic Encephalo · NA · not yet recruiting
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
- NCT07528339 — Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK) · not yet recruiting
- NCT07451028 — Effect of an Oral Neuromuscular Training Device on Dysphagia · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04003181 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Aarhus
- Last refreshed: 8 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04003181.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing